JP2009541383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541383A5 JP2009541383A5 JP2009516960A JP2009516960A JP2009541383A5 JP 2009541383 A5 JP2009541383 A5 JP 2009541383A5 JP 2009516960 A JP2009516960 A JP 2009516960A JP 2009516960 A JP2009516960 A JP 2009516960A JP 2009541383 A5 JP2009541383 A5 JP 2009541383A5
- Authority
- JP
- Japan
- Prior art keywords
- atoms
- hydrogen
- carbon atoms
- replaced
- fluorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 155
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 110
- 125000001153 fluoro group Chemical group F* 0.000 claims 90
- 229910052739 hydrogen Inorganic materials 0.000 claims 52
- 239000001257 hydrogen Substances 0.000 claims 51
- 229910052731 fluorine Inorganic materials 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims 37
- 125000004429 atom Chemical group 0.000 claims 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 26
- 229910052794 bromium Inorganic materials 0.000 claims 22
- 229910052801 chlorine Inorganic materials 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 19
- 229910052740 iodine Inorganic materials 0.000 claims 18
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 13
- 229940002612 prodrug Drugs 0.000 claims 12
- 239000000651 prodrug Substances 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 206010063837 Reperfusion injury Diseases 0.000 claims 8
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 206010040070 Septic Shock Diseases 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- -1 methoxy, methyl Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- RVQOKKHTGALHFH-UHFFFAOYSA-N 2-[[1-(2-cyclohexylethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCC1CCCCC1 RVQOKKHTGALHFH-UHFFFAOYSA-N 0.000 claims 1
- HCFKWZWLHJPSNV-UHFFFAOYSA-N 2-[[1-[2-(4-fluorophenoxy)ethoxy]-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCOC1=CC=C(F)C=C1 HCFKWZWLHJPSNV-UHFFFAOYSA-N 0.000 claims 1
- UPFZIKCYEGCTTD-UHFFFAOYSA-N 2-[[7-[2-(4-fluorophenoxy)ethoxy]-1-benzothiophene-6-carbonyl]amino]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2C=CSC2=C1OCCOC1=CC=C(F)C=C1 UPFZIKCYEGCTTD-UHFFFAOYSA-N 0.000 claims 1
- NJOHIVWMBOEAHQ-UHFFFAOYSA-N 2-methyl-2-[[1-(2-phenoxyethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCOC1=CC=CC=C1 NJOHIVWMBOEAHQ-UHFFFAOYSA-N 0.000 claims 1
- ALNVRBPHNQXFNX-UHFFFAOYSA-N 2-methyl-2-[[1-(2-phenylethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCC1=CC=CC=C1 ALNVRBPHNQXFNX-UHFFFAOYSA-N 0.000 claims 1
- LCCJHTAODKVKBJ-UHFFFAOYSA-N 2-methyl-2-[[1-(2-thiophen-2-ylethoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCC1=CC=CS1 LCCJHTAODKVKBJ-UHFFFAOYSA-N 0.000 claims 1
- MFKVYLDQHQTTEG-UHFFFAOYSA-N 2-methyl-2-[[1-(3-phenoxypropoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCCOC1=CC=CC=C1 MFKVYLDQHQTTEG-UHFFFAOYSA-N 0.000 claims 1
- UUEHRDAKFQMJOI-UHFFFAOYSA-N 2-methyl-2-[[1-(4-phenylbutoxy)-5,6,7,8-tetrahydronaphthalene-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2CCCCC2=C1OCCCCC1=CC=CC=C1 UUEHRDAKFQMJOI-UHFFFAOYSA-N 0.000 claims 1
- DXQGCBPPBDAFTJ-UHFFFAOYSA-N 2-methyl-2-[[4-(2-phenoxyethoxy)-1-benzothiophene-5-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2SC=CC2=C1OCCOC1=CC=CC=C1 DXQGCBPPBDAFTJ-UHFFFAOYSA-N 0.000 claims 1
- IYSMQHIGSAISAY-UHFFFAOYSA-N 2-methyl-2-[[7-(2-phenoxyethoxy)-1-benzothiophene-6-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2C=CSC2=C1OCCOC1=CC=CC=C1 IYSMQHIGSAISAY-UHFFFAOYSA-N 0.000 claims 1
- AJJVRLKVERYLFB-UHFFFAOYSA-N 2-methyl-2-[[7-(2-phenylethoxy)-1-benzothiophene-6-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2C=CSC2=C1OCCC1=CC=CC=C1 AJJVRLKVERYLFB-UHFFFAOYSA-N 0.000 claims 1
- FZZJWKALYVWTDH-UHFFFAOYSA-N 2-methyl-2-[[7-(3-phenylpropoxy)-1-benzothiophene-6-carbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C1=CC=C2C=CSC2=C1OCCCC1=CC=CC=C1 FZZJWKALYVWTDH-UHFFFAOYSA-N 0.000 claims 1
- 125000004011 3 membered carbocyclic group Chemical group 0.000 claims 1
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims 1
- 208000005232 Glossitis Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 claims 1
- 206010020591 Hypercapnia Diseases 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010067472 Organising pneumonia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical group C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims 1
- 208000000292 ehrlichiosis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 230000000222 hyperoxic effect Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000008383 multiple organ dysfunction Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06013591.0 | 2006-06-30 | ||
| EP06013591 | 2006-06-30 | ||
| PCT/EP2007/005577 WO2008000410A1 (en) | 2006-06-30 | 2007-06-25 | Cxcr2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541383A JP2009541383A (ja) | 2009-11-26 |
| JP2009541383A5 true JP2009541383A5 (enExample) | 2010-09-02 |
| JP5352455B2 JP5352455B2 (ja) | 2013-11-27 |
Family
ID=37076116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516960A Expired - Fee Related JP5352455B2 (ja) | 2006-06-30 | 2007-06-25 | Ｃｘｃｒ２阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8980938B2 (enExample) |
| EP (1) | EP2041073B1 (enExample) |
| JP (1) | JP5352455B2 (enExample) |
| WO (1) | WO2008000410A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009009675A1 (de) * | 2009-02-19 | 2010-08-26 | Daimler Ag | Brennstoffzellensystem mit wenigstens einer Brennstoffzelle |
| WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
| US20140095068A1 (en) * | 2012-09-28 | 2014-04-03 | Xerox Corporation | Method and system for reducing traffic congestion |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962224A (en) * | 1987-12-23 | 1990-10-09 | American Home Products Corporation | N-naphthoylglycines as aldose reductase inhibitors |
| US4994477A (en) * | 1988-03-24 | 1991-02-19 | Abbott Laboratories | Heterocyclic renin inhibitors |
| DE59401923D1 (de) * | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6531467B2 (en) * | 1996-09-12 | 2003-03-11 | Idun Pharmaceuticals, Inc. | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| FR2825706B1 (fr) * | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| JP2007501844A (ja) * | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| WO2005023818A2 (en) | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| WO2005051940A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
| BRPI0517567A (pt) * | 2004-11-09 | 2008-06-17 | Smithkline Beecham Corp | composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto |
| EP1676834A1 (en) * | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| AR055319A1 (es) | 2005-03-17 | 2007-08-15 | Wyeth Corp | Derivados de isoquinoleina, composiciones farmaceuticas y usos |
-
2007
- 2007-06-25 EP EP07764813.7A patent/EP2041073B1/en not_active Not-in-force
- 2007-06-25 JP JP2009516960A patent/JP5352455B2/ja not_active Expired - Fee Related
- 2007-06-25 WO PCT/EP2007/005577 patent/WO2008000410A1/en not_active Ceased
-
2008
- 2008-12-18 US US12/337,980 patent/US8980938B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526695A5 (enExample) | ||
| JP2664538B2 (ja) | ベンズアミド | |
| JP5237938B2 (ja) | 新規なｃｘｃｒ２阻害剤 | |
| JP2017504576A5 (enExample) | ||
| NL1028087C2 (nl) | Sulfonamiderivaten voor de behandeling van ziekten. | |
| JP2012532112A5 (enExample) | ||
| RU2007128949A (ru) | Конденсированные бициклические карбоксамидные производные, используемые в качестве ингибиторов схсr2 для лечения воспалений | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| RU2419621C2 (ru) | Гетероциклические соединения, пригодные для использования в качестве анаболических агентов скота | |
| JP5352454B2 (ja) | Ｃｘｃｒ２アンンタゴニスト | |
| AU2015231216B2 (en) | Antifungal compound process | |
| JP2016121196A5 (enExample) | ||
| JP2012530703A5 (enExample) | ||
| JP2010513283A5 (enExample) | ||
| JP2013526494A5 (enExample) | ||
| JP2013510883A5 (enExample) | ||
| JP2009537544A5 (enExample) | ||
| JP2015520130A (ja) | ホルミルペプチド受容体２調節物質としての（２−ウレイドアセトアミド）アルキル誘導体 | |
| EP3119771A1 (en) | Antifungal compound process | |
| JP2009541383A5 (enExample) | ||
| US20160060248A1 (en) | Synthesis of dabigatran | |
| JP2013516475A5 (enExample) | ||
| CA3244893A1 (en) | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4-YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND | |
| JP2013544880A5 (enExample) | ||
| US9951058B2 (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient |